… 8 although in these studies, the drug was frequently used as second-line therapy. Etoposide
(VP-16) is likewise a very effective drug against SCLC with a response rate from cumulative …

… We believe that this study has defined several situations in which VP- I6 combination … VP-16,
we had never seen long survival in this situation and we believe strongly that DDP + VP-16 …

… There is for these patients virtually no efficient salvage therapy including alternative non-cross-resistant
drugs. The antitumor activity of etoposide VP 16-213 (VP-16) has been shown to …

… (an attempt at cellular synchronization by combining VCR‐… In the second protocol the
combination of VP 16.213 (100 mg/m 2 … VP 16.213‐Cyclophosphamide combination in lung …

… , we are currently comparing alternating CAV and VP16/cisplatin for six cycles of treatment
… chemotherapy combinations is a more effective treatment approach in this disease. VP-16 …

… were treated either with VP-16 alone or VP16 and cisplatin. … other drug combinations either
as maintenance therapy or as … cycles of VP- 16-cisplatin combination therapy ranged from 1 …

… compare favorably to our experience with similar patients treated with cisplatin plus VP16
alone. Further studies with VIP as initial salvage therapy for patients with GCT are planned. …

… The role of etoposide epipodophyllotoxin (VP-16-213) in a combined modality treatment
program incorporating local chest irradiation and combination chemotherapy with …

… improvement in survival when VP-16-213 was given 4 h after VCR. However, as in the
current study, 'more than additive therapy' was observed with lower dose combinations when …

… all patients without prior VP16-213 therapy; group 2 represents those patients having
received VP-16-213 at standard dose and progressed prior to high-dose therapy. In group 2, all …